AU686101B2 - Creación de Inventos y Patentes con Inteligencia Artificial

AU686101B2 – Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
– Google Patents

AU686101B2 – Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
– Google Patents
Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides

Download PDF
Info

Publication number
AU686101B2

AU686101B2
AU41083/93A
AU4108393A
AU686101B2
AU 686101 B2
AU686101 B2
AU 686101B2
AU 41083/93 A
AU41083/93 A
AU 41083/93A
AU 4108393 A
AU4108393 A
AU 4108393A
AU 686101 B2
AU686101 B2
AU 686101B2
Authority
AU
Australia
Prior art keywords
mammal
antigen
nonself
class
syngeneic
Prior art date
1992-04-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU41083/93A
Other versions

AU4108393A
(en

Inventor
Charles B. Carpenter
David A. Hafler
Mohamed Sayegh
Howard L. Weiner
Zhengi Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Autoimmune Inc

Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1992-04-20
Filing date
1993-04-20
Publication date
1998-02-05

1993-04-20
Application filed by Autoimmune Inc
filed
Critical
Autoimmune Inc

1993-11-18
Publication of AU4108393A
publication
Critical
patent/AU4108393A/en

1998-02-05
Application granted
granted
Critical

1998-02-05
Publication of AU686101B2
publication
Critical
patent/AU686101B2/en

2013-04-20
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K39/00—Medicinal preparations containing antigens or antibodies

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

C07K14/70503—Immunoglobulin superfamily

C07K14/70539—MHC-molecules, e.g. HLA-molecules

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K39/00—Medicinal preparations containing antigens or antibodies

A61K39/0005—Vertebrate antigens

A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K39/00—Medicinal preparations containing antigens or antibodies

A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P37/00—Drugs for immunological or allergic disorders

A61P37/02—Immunomodulators

A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K38/00—Medicinal preparations containing peptides

Abstract

Described are methods for: (a) suppressing the ability of T-cells from a mammal to proliferate in response to stimulation by nonself mammalian tissue; and (b) suppressing immune response which leads to allograft rejection in a mammal receiving an allograft from a donor mammal. The methods involve orally administering to the mammal to be thus treated a composition comprising at least one of: (i) a major histocompatibility complex Class II antigen from a second nonself mammal or from tissue of a mammal syngeneic to said nonself mammal; (ii) at least one synthetic peptide corresponding to a T-cell suppressive fragment of said Class II antigen, said composition being administered in an amount effective to suppress said proliferation. The foregoing compositions are also described.

Description

WO 93/20842 PCr/US93/03708 SUPPRESSION OF PROLIFERATIVE RESPONSE AND INDUCTION OF TOLERANCE WITH POLYMORPHIC CLASS II MHC ALLOPEPTIDES FIELD OF THE INVENTION The present invention is directed to formulations and methods for suppressing lymphocyte proliferation and controlling the immune response of mammals against the introduction of foreign tissue. The invention also includes methods for prolonging the survival of transplanted organs and tissues.
Recent work with synthetic peptides representing portions of the polymorphic regions of mouse and human Class I and II major histocompatibility complex (MHC) molecules indicates that they can be bound to MHC molecules and elicit a T cell response in vitro (Benichou, et al. (1990) J. Exp. Med. 172: 1341-1346; Nuchtern, et al. (1990) Nature 343: 74-76; Olson, et al. (1989) Proc. Natl. Acad. Sci. USA 86: 1031- 1035; Parham, et al. (1987) Nature 325: 625-628; and Chen, et al. (1991), J. Exp. Med. 172: 779-788). There is no information on the induction of immunity or tolerance by administration of synthetic MHC peptides in vivo. The oral route of administration of antigens has been shown to induce immune hyporesponsiveness (Mowat, A. (1987) Immunology Today 8: 93-98).
In the parent application, we have disclosed that oral administration of allogeneic splenocytes to inbred rats downregulates the systemic cell mediated immune response in vitro and in vivo.
WO 93/20842 PCT/US93/03708 2 BRIEF DESCRIPTION OF THE FIGURES Figure 1: Amino acid sequences of the synthetic MHC RT1.Bu and RT1.D peptides aligned with those of RT1′. Dots denote unknown sequences while dashes denote identical sequences.
Stars denote absent sequences.
Figure 2: A. Direct proliferation of lymphocytes harvested from naive and immunized (with the entire allopeptide mixture) animals and incubated with the entire peptide mixture (PEP.MIX), RT1.B, or RT1.D allopeptides. Bars represent mean cpm +SEM of a representative experiment performed in quadruplicates experiments).
B. Proliferation of nylon wool non-adherent mononuclear cells harvested from immunized (with the entire allopeptide mixture) animals to the entire peptide mixture (PEP.MIX), RT1.B, or RT1.D allopeptides presented by syngeneic nylon wool adherent cells. Bars represent mean cpm ±SEM of a representative experiment performed in quadruplicates (4 experiments).
Figure 3: A. DTH responses of naive and immunized (with the entire allopeptide mixture, 5 experiments) animals challenged with the peptide mixture (Peptides) or WF splenocytes (Cells).
Bars represent mean delta ear thickness in inches x10′ 2 (±SEM) of a representative experiment (n=5 in each group).
B. DTH responses of RT1.B immunized (4 experiments) or RT1.D immunized (5 experiments) animals challenged with the respective allopeptides (Peptides) or WF splenocytes (Cells). Bars represent mean delta ear thickness in inches xl0′ (±SEM) of a representative experiment (n=5 animals in each group).
Figure 4: A. Reduction of DTH responses by oral administration of the entire allopeptide mixture. Experiment 1, lower panel: animals were immunized with the entire allopeptide mixture and challenged with the peptide mixture (Peptides) or WF splenocytes (Cells). Experiment 2, upper panel: animals were immunized with the entire allopeptide mixture and challenged with WO ./V20842 PCT/US93/03708 3 the peptide mixture (Peptides) or mycobacterium tuberculosis Bars represent mean delta ear thickness in inches (±SEM) (n=5 animals in each group) of control (CONTROL 1 and 2) and peptide fed (FED MIXED) animals.
B. Reduction of DTH responses by oral administration of RT1.B or RT1.D allopeptides. Animals were immunized with RT1.B or RT1.D and challenged with the respective allopeptides (Peptides) or mycobacterium tuberculosis (Cells).
Bars represent mean delta ear thickness in inches x10 2
(±SEM)
(n=5 animals in each group) of control (CONT RT1.B, CONT RT1.D) and peptide fed (FED RT1.B, Fed RT1.D) animals (2 experiments).
Figure 5 is a bar graph of DTH responses of animals immunized with the individual four fragments of RT1.B and RT1.D and challenged with the respective allopeptide.
Figure 6: Amino acid sequences of the synthetic MHC RT1.Bfl, RT1.Bf
B
RT1.Df l and RT1.Df’ peptides. Dots denote unknown sequences while dashes denote identical sequences. Stars denote absent sequences.
Figure 7: A graphic illustration of graft survival rate after receipt of allografts.
Figure 8: A graphic illustration of allograft functions as evidenced by serum creatinine.
SUMMARY OF THE INVENTION The immunogenicity and tolerogenicity of Class II major histocompatibility complex (MHC) allopeptides were tested in the rat in vivo. Inbred LEW (RT1′) rats, used as responders, were immunized in the foot pad with a mixture of 8 Class II synthetic MHC allopeptides emulsified in complete Freund’s adjuvant. The sequences of these peptides represented the full length second domain of RT1.B and RT1.D» (WF) 0 chains. In vitro, responder lymphocytes harvested from popliteal and inguinal lymph nodes of immunized animals exhibited significant proliferation to the MHC allopeptide mixture. In addition, these responder lymphocytes significantly proliferated to allogeneic WF (RT1″) stimulator cells, when compared to naive controls in the standard one-way 4 mixed lymphocyte response (MLR) (relative response: 2.65 4- 0.2, n In-viy, peptideimmunized LEW animals were challenged in the ear 2 weeks after immunization with either the allopeptide mixture or freshly prepared and irradiated allogeneic WF splenocytes. When compared to naive controls, these animals had significant delayed type hypersensitivity (DTH) responses both to the allopeptide mixture and to allogeneic (WF) splenocytes, but not to syngeneic LEW or third party allogeneic (BN) splenocytes.
Oral administration of the allopeptide mixture to LEW responder rats daily for 5 days before immunization resulted in a significant reduction of DTH responses both to the allopeptide mixture (77 reduction, p 0.002) and to allogeneic (WF) splenocytes (70 reduction, p 0.008). This reduction was antigen specific, since there was no reduction of DTHresponses to mycobacterium tuberculosis.
These data demonstrate that lymphocytes from animals immunized with polymorphic Class II MHC allopeptides can recognize and proliferate to the same amino acid sequences present on allogeneic cell surface MHC molecules. In addition, oral administration of these peptides downregulates the systemic cell-mediated immune response in a specific fashion. The present invention is directed to use of synthetic MHC allopeptides to provide specific suppression of proliferative lymphocyte response to Class II MHC antigens of allogeneic tissue and to induce specific immune tolerance to allografts.
According to one embodiment of the invention, there is provided a method for suppressing the ability of T-cells from a mammal to proliferate in response to stimulation by nonself mammalian tissue comprising orally administering to said mammal a composition comprising at least one member selected from the group consisting of: major histocompatibility complex Class II antigen from the nonself mammal or from tissue of a mammal syngeneic to said nonself mammal; (ii) at least one synthetic peptide corresponding to a T-cell suppressive fragment of said Class II antigen, said composition being administered in an amount effective to suppress said proliferation.
According to another embodiment of the invention, there is provided an oral formulation which upon oral administration of an effective amount to a mammal suppresses the ability ofTcells to proliferate in response to stimulation by allogeneic tissue, comprising a major histocompatibility complex Class II antigen from a nonself mammal or from tissue of a mammal syngeneic to said nonself mammal.
According to another embodiment of the present invention there is provided an oral formulation which upon oral administration of an effective amount to a mammal suppresses the ability of T-cells to proliferate in response to stimulation by allogenic tissue comprising at least one synthetic peptide corresponding to a T-cell suppressive fragment of a major histocompatibility complex class II antigen from the nonself mammal or from tissue of a mammal syngeneic to said nonself mammal.
DETAILED DESCRIPTION OF THE INVENTION Throughout this specification and the appended claims, unless the context requires otherwise, the word «comprise», or variations such as «comprises» or «comprising», will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers, All cited documents are incorporated by reference in their entirety.
The availability of sequence data for the variable domains of MHC molecules has made it possible to synthesize peptides representing various portions of the native cell surface molecules and to use these peptides to assess immunogenicity and tolerogenicity. The data show that rat polymorphic Class II P MHC allopeptides of 2 loci, RTl.BP and RT.DP, are immunogenic WO 93/20842 I>GT/ JUS93/03708 in vivo as assessed by lymphocyte proliferation in vitro and by DTH responses in vivo. Moreover, when administered orally, these MHC allopeptides are tolerogenic; they induce a state of immune hyporesponsiveness which is antigen-specific.
The data also show that, in addition to polymorphism, the native location of the allopeptide, 1-pleat vs. a-helix, appears to be an important determinant of immunogenicity and tolerogenicity. These experiments test the ability of responder (LEW) antigen-presenting cells to bind the f-pleat allopeptide fragments. The a-helix allopeptides serve as negative controls.
Although autologous sequences could also be used for these studies, the work of Benichou et al., J. Exp. Med. 172: 1341-1346 (1990) in the mouse suggests that self-tolerance may not develop to autologous f-pleat sequences. These authors screened five autologous class II mouse MHC peptides and showed that two 3pleat fragments can bind to self MHC molecules and are immunogenic, and that neonatal tolerance could be induced after intraperitoneal injection of an immunogenic peptide. Similar in vitro immunogenicity data in humans have been presented by Liu and Suciu-Foca, Hum. Immunol. 32 (Suppl.), 4 (1991) using allopeptide fragments derived from the first domain of HLA-DRB1*0101. Only a f-pleat fragment was immunogenic in the example studied by these co-authors.
Recent work with mouse and human peptides, representing portions of the polymorphic regions of Class I and II MHC molecules, indicates that exogenous allopeptides and self peptides are taken up by antigen presenting cells in vitro and presented on MHC molecules, presumably by the endogenous process of pinocytosis, processing in the Golgi, and transport to the cell surface bound to an MHC molecule for recognition.
Demonstration by Chen et al., supra, that a Class I synthetic peptide can be presented on an intact Class II molecule via the exogenous pathway shows that some T cell clones recognize alloantigen which has been processed and presented as peptides in a self-MHC binding site. Self-MHC or allo-MHC peptides may WO 93/2042 PCI/ US93/03708 6 therefore be processed in a manner identical to any other peptide moiety, although recognition of intact MHC molecules which bind endogenous peptides may be a major route of acquisition of immunity to cells or grafts (Eckels, D.D. (1990) Tissue Antigens 35: 49-55). The present data demonstrate that animals immunized with Class II MHC allopeptides will recognize and respond to allogeneic cells in vitro and in vivo, indicating that a significant number of T cell clones will recognize polymorphic amino acid sequences on intact cell surface MHC molecules.
(Alternatively, the targets could be peptides presented by alloor self-MHC.) The route of administration of MHC allopeptides and the qualitative and quantitative aspects of peptide processing and presentation could be determinants of the induction of immunity or tolerance to alloantigens.
Introduction of autoantigens into the intestinal tract will suppress the immune response in several experimental autoimmune models (Mowat, et al., supra). The most extensively studied is the experimental autoimmune encephalomyelitis (EAE) (Higgins, et al. (1988) J. Immunol 140: 440-445; Khoury, et al. (1990) Cell Immunol. 131: 302-310; and Whitacre, et al. (1986) J. Immunol. 144: 2115-2163. Other experimental models where oral administration of antigen results in immunologic unresponsiveness or «oral tolerance» include experimental autoimmune uveoretinitis (Nussenblatt, et al., J_ Immunol. 144:1689-1695, 1989), collagen-induced and adjuvantarthritis (Nagler-Anderson, et al. (1986) Proc. Natl. Acad.
Sci. USA 83: 7443-7446; and Zhang, et al. (1990) J_ Immunol. 145: 2489-2493), and diabetes in NOD mice (Zhang, Z.J., et al. (1991) Proc. Natl. Acad. Sci. USA 88: 10252-10256). The mechanisms mediating the tolerizing effects of oral administration of antigen have been studied in the EAE model where it is possible to adoptively transfer prbtection against EAE with CD+8 cells from mesenteric lymph nodes and spleens of animals orally tolerized with myelin basic protein (Lider, et WO 93/20842 2PCI/US93/03708 7 al. (1989) J. Immunol. 142: 748-752). More recently, Miller et al. showed that these suppressor T cells suppress in vitro and in vivo immune responses by the release of TGF-01. Others have reported that clonal anergy may also play a role in oral tolerance for MBP in EAE (Whitacre, et al., J. Immunol, 147:2155- 2163). There is initial evidence in EAE that synthetic peptides can induce tolerance after oral administration (Higgins, et al., J. *Immunol. 140:440-445) In the mouse, intravenous CI1.
26 peptide (amino acids 12-26 of lambda repressor protein) produces long term tolerance which does not function by a suppressor mechanism, and is presumably mediated by T cell anergy. In the alloimmune system, we have shown that oral administration of allogeneic splenocytes to inbred rats down-regulates the cell mediated immune response to histocompatibility antigens and prevents sensitization by transplants or allografts (data not shown), We have also demonst’:ated that oral administration of allogeneic splenocytes is associated with selective inhibition of responder (Type 1 T-helper) Thl-like cell function, and that this inhibition may be mediated by inhibitory cytokines secreted by CD4+ Th2-like cells (Hancock, et al., J. Am. Soc. Neph.
2:782 (1991)). The present experiments demonstrate that oral administration of Class II MHC allopeptides to inbred rats induces a state of specific immunologic hyporesponsiveness; either RTI.D or RT1.B 0 chain peptides produce comparable reduction of DTH response to whole spleen cells which bear both sets of incompatibilities, as well as a chain and RT1.H Class II, and RT1.A Class I, differences. Therefore, induction of negative regulatory pathways must play a major role in this form of tolerance. This can be used to advantage to induce tolerance to grafts or transplanted organs.
There are data to indicate that peptides presented on Class I MHC molecules are nonomers (Falk, et al. (1991) Nature 351: 290-296), while those presented by Class II MHC molecules are 13-17 amino acids in length (Rudensky, et al.
(1991) Nature 353: 622-627). There are no such data available WO 93/20842 W /J/U5S93/03708 for MHC allopeptides.
The mechanisms by which oral and intravenous administration of allogeneic splenocytes prevents sensitization by skin allografts were also studied. LEW rats were sensitized with BN skin allografts 7 days prior to receiving heterotopic (LEWxBN)Fl vascularized cardiac allografts. While unsensitized cardiac allografts were rejected on day 6-8, control sensitized grafts were rejected within 24-48 hours. Oral administration of BN splenocytes during the sensitization phase (between skin and heart grafting) prevented this accelerated allograft rejection and prolonged cardiac allograft survival to 7 days. Intravenous administration of BN splenocytes (50×10 6 daily for 5 days starting on day of skin grafting) also prevented accelerated cardiac allograft rejection and prolonged graft survival to 9+1 days Immunoperoxidase studies of cardiac allografts harvested 24-48 hours post-transplant showed that when compared to sensitized controls, animals which received oral splenocytes had reduced deposition of IgG (1/1000 vs 1/4000,), IgM (1/1000 vs 1/6000), C3 (1/4000 vs 1/16000) and fibrin (1/4000 vs 1/16000) titers in the graft. There was also decreased cellular infiltration with macrophages (18±8 vs 3718 cells/HPF, p<0.01), T cells (5+3 vs 19±7, p<0.01), and IL-2R+ T cells (5+3 vs 15+4, p<0.01). In addition, there was significant reduction of infiltrating mononuclear cells stained with antibodies to IL-1, IL-2, IL-6, IL-8, IFN-y, and TNF. In contrast, these grafts showed markedly increased IL-4 staining (most mononuclear and all endothelial cells), as compared to control grafts (20% of mononuclear cells and only focal endothelium). Comparative immunoperoxidase studies of cardiac allografts harvested from animals which received the intravenous splenocytes showed similar changes of reduced humoral deposits and cellular infiltrates as seen in the oral splenocytes group, but cytokine staining 'as different; there was increased staining for both IL-1 on endothelium and IFN-y on NK cells, while IL-4 staining was not increased relative to control grafts. WO 93/20842 W) 2Gr 1S93/03708 9 Therefore, both oral and intravenous administration of alloantigen down-regulate the immune system but by different mechanisms. Oral administration of alloantigen effects selective inhibition of Thl-like cell function (IL-2 and IFN-y production), and activation of Th-2 like cells which secrete inhibitory cytokines (IL-4 and possibly IL-10). The mode of action of intravenous alloantigen administration may involve a transient state of T cell anergy. EXPERIMENTAL 1. Animals: LEW, WF, and BN rats, 8-10 weeks old, were obtained from Harlan Sprague Dawley Inc. (Indianapolis, IN) or were bred inhouse. 2. Allopentides: The RT1.B f and RT1.D 0 domains of RT1" (WF) were selected, and 4 overlapping peptides of 24-25 amino acids (1-25, 20-44, 39-64, 68-92 for RT1.B, and 1-25, 44, 39-64, 60-84 for RT1.D) were synthesized by solid phase synthesis for each locus a total of 8 peptides), using published sequences of the Class II f chain (Chao, et al. (1989) Immunogenetics 29: 231-234). Figure 1 shows these polymorphic sequences aligned with those of the f chains of RT11 (LEW). Peptides which were used for in vitro proliferation assays were purified by high pressure liquid chromatography yielding 95% purity as determined by amino acid analysis. 3. Proliferation Assay: Responder LEW rats were immunized subcutaneously in the foot pad with 100pg of the mixture of the four RT1.B and four RT1.D peptides (12.5pg each) in complete Freund's adjuvant,, Popliteal and inguinal lymph nodes were harvested 1 week after immunization and mashed through sterile stainless steel sieves. The recovered cells were then washed twice and resuspended into RPMI 1640 medium (Microbiological Associates Inc.), containing 10% fetal calf serum, 100U/ml penicillin and 100Ag/ml streptomycin, 2x10'M 2mercaptoethanol, and 5mM HEPES. T and B cells were separated by nylon adherence as described (Frankel, et al. (1989) Transplantation 48: 639-646). Responder unseparated LEW WO 93/20842 W 8CXriUS93/03708 lymphocytes (3x10 5 were cultured in 96-well flat bottom plates (Costar) with 10-50g of the mixture of RTI.B", RTI.D", or both, sets of allopeptides for 30 minutes at 37 C. The cells were then washed twice to remove excess peptides before adding the nylon wool nonadherent responder T cells (2x10 5 Negative control wells were set up with culture medium only. LEWxWF one way MLRs were set up by using equal numbers of responder LEW and allogeneic WF stimulator lymphocytes (prepared as described for LEW lymphocytes and irradiated with 3000 Rads) per well. The plates were incubated at 37 C with 5% CO, for four days before they were pulsed for 6 hours with 3 H-thymidine (ltCi/well, NEN Dupont) and harvested with a PHD cell harvester (Cambridge Technology). Proliferation was assayed by 3H-thymidine incorporation measured by a Beckman liquid scintillation counter. Experiments were set up in quadruplicates, and results expressed as mean counts per minute or relative response (Experimental-Background cpm). (Control-Background cpm) 4. Delayed Type Hypersensitivity (DTH) Response: LEW rats, used as responders, were immunized subcutaneously in the foot pad with 100g of the mixture of four RT1.Bu (50g) and four RT1.D" (50Ag) peptides in complete Freund's adjuvant (12.5g of each peptide). These animals were challenged subcutaneously 2 weeks later in one ear with 10pg of the peptide mixture and in the other ear with freshly prepared and irradiated (3000 Rads) splenocytes (10x10 6 from WF (RT1u), syngeneic LEW or third party BN The DTH responses were measured with micrometer caliper (Mitutoyo, Japan) by a blinded observer as the delta ear thickness before and 2 days after the challenge (inches x10" 2 Experiments were performed using 5 animals in each study group. P values were calculated using the student t-test. Example 1: Assessment of the Immunogenicity of Class II MHC Allopeptides In Vitro WO 93/20842 Pcr/US93/03708 11 In order to test the immunogenicity of the synthetic RT1.B and RTI.D allopeptides, lymphocytes harvested from responder LEW animals immunized with the mixture of 8 allopeptides 1 week earlier were compared to naive controls for their ability to proliferate to the allopeptides in a standard 96 hour proliferation assay. As shown in Figure 2A, while naive lymphocytes had only minimal proliferation, immunized animals exhibited significant proliferation to the allopeptide mixture, as well as to individual allopeptides of RT1.B (4 peptides) and RT1.D (4 peptides). In addition, when compared to naive controls, responder lymphocytes from immunized animals exhibited significantly increased proliferation to allogeneic WF stimulator cells in the standard one way MLR (relative response 2.65±0.2, n=6, data not shown). In order to formally test whether syngeneic antigen presenting cells can bind and present MHC allopeptides, nylon wool adherent LEW lymph node cells were preincubated with the entire allopeptide mixture, or with the RT1.B or RT1.D allopeptides separately. After washing, responder T cells were added to the cultures. Figure 2B shows that T cells from immunized animals proliferate to syngeneic antigen presenting cells which had been preincubated with the MHC allopeptides. These data demonstrate that the synthetic Class II MHC allopeptides are immunogenic in vivo, as assessed by lymphocyte proliferation in vitro. Furthermore, lymphocytes from animals immunized with these allopeptides proliferate more vigorously to allogeneic cell surface MHC molecules. Example 2: Immunocenicity of Class II MHC Allopeptides by DTH In Vivo LEW animals which were immunized with the entire allopeptide mixture had significant DTH responses both to the allopeptides and to freshly prepared allogeneic WF splenocytes (Figure 3A). These responses were antigen specific, since the immunized animals had minimal DTH responses to syngeneic LEW (delLa ear thickness in inches x10' 2 0.22+0.07 vs 0.67±0.06, p WO 93/20842 PCT/US93/03708 12 0.001, n=5 in each group) or allogeneic third party BN splenocytes (delta ear thickness 0.12+0.06 vs 0.67+0.06, p 0.001, n=5 in each group). In addition, immunization with RT1.B or RT1.D allopeptides separately resulted in significant DTH responses both to the respective allopeptide mixture and to allogeneic WF splenocytes (Figure 3B). These data further demonstrate that the synthetic Class II MHC allopeptides are immunogenic in vivo, and that lymphocytes from animals immunized with these allopeptides can respond to polymorphic amino acid sequences on, or derived from, allogeneic cell surface MHC molecules. Example 3: ToleroQenicity of Orally Administered Class II MHC Allopeptides The ability of synthetic Class II MHC allopeptides to induce immune hyporesponsiveness after oral administration was assessed as follows: LEW responder animals were fed 100g of the entire allopeptide mixture (8 peptides, 12.5pg each), or 50pg of RT1.B or RT1.D, by gavage daily for 5 days. Three days after the last feeding the animals were immunized with the allopeptide mixture and DTH responses determined 2 weeks later. Figure 4A (lower panel) shows that animals fed all 8 peptides had significantly marked reduction of DTH responses to the same allopeptide mixture (77% reduction, p 0.001) as well as to WF splenocytes (70% reduction, p 0.003), when compared to unfed controls. This reduction was antigen specific since there was no reduction of DTH responses to mycobacterium tuberculosis (the antigen present in complete Freund's adjuvant) (Figure 4A, upper panel). When either RT1.B or RTI.D allopeptides were fed separately (Figure 4B), significant reduction of antigen specific DTH responses was effected (RT1.B 47%, p 0.001, and RT1.D 67%, p 0.001). In addition, oral administration of either allopeptide mixture resulted in significant reduction of DTH responses to allogeneic WF splenocytes (RT1.B 42% and RT1.D 48%, p 0.05, n=5 in each group, data not shown). These data indicate that oral administration of polymorphic Class II MHC allopeptides down-regulates the systemic cell mediated response WO 9./208,12 IY' U893/03708 13 to subsequent immunization, and that this down-regulation is specific to the orally administered antigens. In vitro, cervical lymph node cells harvested 3 days after the last feeding from naive animals which received the oral allopeptide mixture exhibited a marked reduction of MLR proliferation to WF stimulator cells as compared to naive controls (73% reduction, n=3, p 0.001, data not shown). Example 4: Specificity of Immunogenicity and Tolerogenicity of Class II MHC Allopeptides. These experiments investigate whether, in addition to polymorphism, the native location of the allopeptide, f-pleat vs. a-helix, may be an important determinant of immunogenicity and tolerogenicity in vivo. The immunogenicity and tolerogenicity of the individual allopeptide fragments were investigated. LEW rats, used as responders, were immunized subcutaneously in the foot pad with 12.5 yg of one of the four RT1.D (1-25, 20-44, 39- 64, and 60-84) and four RT1.B (1-25, 20-44, 39-64, and 68-92) allopeptide fragments and CFA. DTH responses were then determined for each of the peptide fragments. As seen in Fig. 5, only the first (RT1.B1 and RTl.DI, both 1-25) and second (RT1.B2 and RT1.D2, both 20-44) fragments corresponding to the f-pleat of both RT1.B and RT1.D, were immunogenic. In Fig. 5, "RT1D mix" and "RT1B mix" refers to animals immunized with a mixture of all four allopeptides. In Fig. 5 solid bars represent immunization with cells, hatched bars represent immunization with peptides. Bars represent the change in ear thickness in inches x 102 (mean SEM). Oral administration of 25 pg of the combined immunogenic allopeptide fragments RT..D1 plus RT1.D2 (12.5 yg each) but not RT1.D3 (39-64) plus RT1.D4 (60-84) resulted in significant reduction of DTH response to the RT1.D allopeptide mixture reduction (P 0.005) vs. 14% reduction (P not significant); n in each group). These observations, in addition to showing that the native location of the allopeptide (f-pleat vs. a-helix) is an important determinant of immunogenicity and tolerogenicity, also provide negative peptide controls for the observed specific- WO 93/20842 WPCT/ US93/03708 14 ity of immunogenicity and tolerogenicity. Example In the following experiment, induction of antigenspecific tolerance to allografts is achieved by injection of polymorphic Class II MHC oligopeptides according to the invention. A mixture of equal amounts (by weight) of the 8 synthetic 25-mer peptides from Example 4 representing full sequences of both RT1.B3' and RT1.DO (Figure 6) at a collective concentration of 1 mg/ml in phosphate buffer saline (PBS) was prepared. Aliquots of this preparation (50z1 in each thymol lobe) were injected intrathymically in adult male LEW rats 48 hours before these rats receive WF or "third-party" BN renal allografts. Negative controls received PBS alone. BN-grafted animals that received intrathymic RT1.B and RT1.Dfl, animals that received intrathymic RT1.Da (100 gg (50 ig each thymol lobe)), animals that received intrathymic RT1.B" or RT1.D# (100 jg (50 ig each thymol lobe)), animals that received intravenous RT1.BS" and RTI.DP and animals that received intrathymic RT1.Bl' and RT1.B (100 4g (50p each thymol lobe)) followed by thymectomy on the day of the transplant were the positive controls. No animals received immunosuppression or antibodies. The results were as follows: WO 93/20842 PCT/US93/03708 Group Survival (days) Intrathymic RT1.Bf" RT1.D" WF Grafts 7, 8, 10, >144, 145, 149, 179, 185, 186 Negative Control Intrathymic PBS 6, 6, 7, 7, 8, Positive Controls Intrathymic RT1.B RT1.D» BN Grafts 6, 7, 7, 7, 8, 9 Intrathymic RT1.D 6, 9, 9, Intrathymic RT1.Bfl» or 5, 6, 7, 7, 7, 8, 8, 9 RT1.Dpr Intravenous RT1.B3″ 8, 8, 9, RT1. DfS Intrathymic RT1.B0’1 8, 9, 10, RT1.DO (thymectomy on day of transplant) Negative and «third-party» (BN grafts) control animals rejected their grafts within 6-10 days as evidenced by serum creatinine levels of 2.8 3.2 mg/dl (Figure By contrast, 6 out of 9 animals injected intrathymically with Class II MHC peptides displayed significant tolerance, have not rejected their kidneys and have survived with normal allograft function (Figure These data indicate that adult thymic T-cells recognize allo-MHC oligopeptides and promote development of antigen-specific peripheral immune tolerance. Polymorphic f chains of Class II MHC allopeptides alone were sufficient to down-regulate the immune response to vascularized renal allografts, confirming and emphasizing the critical role of T-cell recognition of Class II MNC antigens in mediating allotolerance. However, intrathymic injection of RT1.B3l or RT1.Dl alone was insufficient to prolong allograft survival. Furthermore, the alpha chain of Class II MHC, which is presumed to be non-polymorphic and is non-immunogenic in an in vivo delayed type hypersensitivity response model, WO 93/20842 PCIYUS93/O3778 16 did not prolong survival. These data indicate the specificity of thymic recognition of polymorphic Class II allo MHC sequences in induction of systemic tolerance to vascularized grafts.
The rejection of allografts within 8-10 days by those animals that received the allopeptide mixture intravenously or those animals that underwent thymectomy on the day of renal transplantation suggests (however, applicants do not intend to be bound’ by the theory) that intrathymic injection of polymorphic Class II MHC allopeptides induces a regulatory cell which down regulates the peripheral alloimmune response or anergizes peripheral T-cell clones.
It is believed that the effects seen herein could be enhanced by administration of immunosuppressive agents such as anti-lymphocytic serum or cyclosporin.

Claims (9)

1. A method for suppressing the ability of T-cells from a mammal to proliferate in response to stimulation by nonself mammalian tissue comprising orally administering t6 said mammal a composition comprising at least one member selected from the group consisting of: (i) major histocompatibility complex Class II antigen from the nonself mammal or from tissue of a mammal syngeneic to said nonself mammal; (ii) at least one synthetic peptide corresponding to a T-cell suppressive fragment of said Class II antigen, said composition being administered in an amount effective to suppress said proliferation.

2. A method for suppressing immune response which lead; to allograft rejection in a mammal receiving an allograft from a donor mammal comprising: prior to said rejection orally or enterally administering to said mammal a composition comprising at least one member selected from the group consisting of a Class II major histocompatibility complex antigen from the donor mammal or from a mammal syngeneic to the donor mammal; (ii) a synthetic peptide corresponding to a T-cell suppressive fragment of said Class I antigen, said composition being administered in an amount effective to suppress said response.

3. An oral formulation which upon oral administration of an effective amount to a S mammal suppresses the ability of T-cells to proliferate in response to stimulation by allogeneic tissue, comprising a major histocompatibility complex Class II antigen from a nonself mammal or S from tissue of a mammal syngeneic to said nonself mammal.

4. An oral formulation which upon oral administration of an effective amount to a mammal suppresses the ability of T-cells to proliferate in response to stimulation by allogenic tissue comprising at least one synthetic peptide corresponding 😮 a T-cell suppressive fragment of a major histocompatibility complex class n antigen from the nonself mammal or from tissue of a mammal syngeneic to said nonself mammal. S S

5. An oral formulation which upon oral administration of an effective amount to a mammal suppresses immune response which leads to allograft rejection in a mammal, comprising major histocompatibility complex Class II antigen from a donor mammal or from a mammal syngeneic to the donor mammal.

6. An oral formulation which upon oral administration of an effective amount to a mammal suppresses immune response which leads to allograft rejection in a mammal comprising at least one synthetic peptide corresponding to a T-cell suppressive fragment of a major histocompatibility complex class II antigen from a donor mammal or from a mammal syngeneic to the donor mammal.

7. A solid oral pharmaceutical dosage form which upon oral administration of an effective amount to a mammal suppresses the ability of T-cells to proliferate in response to stimulation by allogenic tissue comprising a major histocompatibility complex class II antigen from the nonself mammal or from tissue of a mammal syngeneic to said nonself mammal. i-i 1 N sx I

8, A solid oral pharmaceutical dosage form which upon oral administration of an effective amount to a mammal suppressen the ability of T-cells to proliferate in response to stimulation by allogenic tissue, comprising at least one synthetic peptide corresponding to a T-ceil suppressive fragment of a major hittocompatibility complex class II antigen from a nonself mammal or from tissue of a mammal syngeneic to said nonself mammal.

9. A solid oral pharmaceutical dosage form which upon oral administration of an effective amount to a mammal suppresses immune response which leads to allograft rejection in a mammal, comprising a major histocompatibility complex class II antigen from a donor mammal or from a mammal syngeneic to the donor mammal. A solid oral pharmaceutical dosage form which upon oral administration of an effective amount to a mammal suppresses immune response which leads to allograft rejection in ‘a mammal, comprising at least one synthetic peptide corresponding to a T-cell suppressive fragment of a major histocompatibility complex class II antigen from the donor mammal or from a mammal syngeneic to the donor mammal. DATED this 31st day of October, 1997 AUTOIMMUNE, INC. to by its Patent Attorneys DAVIES COLLISON CAVE S *o I *t t o 8* l

AU41083/93A
1992-04-20
1993-04-20
Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides

Ceased

AU686101B2
(en)

Applications Claiming Priority (9)

Application Number
Priority Date
Filing Date
Title

US87128992A

1992-04-20
1992-04-20

US871289

1992-04-20

US96177992A

1992-10-15
1992-10-15

US961779

1992-10-15

US97773792A

1992-11-13
1992-11-13

US977737

1992-11-13

US08/027,127

US5593698A
(en)

1990-10-31
1993-03-05
Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides

US027127

1993-03-05

PCT/US1993/003708

WO1993020842A1
(en)

1992-04-20
1993-04-20
Suppression of proliferative response and induction of tolerance with polymorphic class ii mhc allopeptides

Publications (2)

Publication Number
Publication Date

AU4108393A

AU4108393A
(en)

1993-11-18

AU686101B2
true

AU686101B2
(en)

1998-02-05

Family
ID=27487557
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU41083/93A
Ceased

AU686101B2
(en)

1992-04-20
1993-04-20
Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides

Country Status (13)

Country
Link

US
(1)

US5593698A
(en)

EP
(1)

EP0637249B1
(en)

JP
(1)

JPH07505892A
(en)

KR
(1)

KR100275656B1
(en)

AT
(1)

ATE205400T1
(en)

AU
(1)

AU686101B2
(en)

BR
(1)

BR9306345A
(en)

CA
(1)

CA2118502A1
(en)

DE
(1)

DE69330752D1
(en)

HU
(1)

HUT71310A
(en)

IL
(1)

IL105472A
(en)

NO
(1)

NO943967L
(en)

WO
(1)

WO1993020842A1
(en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

IL99699A
(en)

1990-10-10
2002-04-21
Autoimmune Inc
Pharmaceutical oral, enteral or by-inhalation dosage form for suppressing an autoimmune response associated with type i diabetes

US6156306A
(en)

1994-08-17
2000-12-05
Albert Einstein College Of Medicine Of Yeshiva University
Pancreatic β-cells for allogeneic transplantation without immunosuppression

GB9505784D0
(en)

1995-03-22
1995-05-10
Lynxvale Ltd
Anti-tumour treatment

US7361331B2
(en)

1996-10-18
2008-04-22
Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food
Plant bioreactors

US6617171B2
(en)

1998-02-27
2003-09-09
The General Hospital Corporation
Methods for diagnosing and treating autoimmune disease

US6599710B1
(en)

1999-03-10
2003-07-29
The General Hospital Corporation
Treatment of autoimmune disease

US7348005B2
(en)

2000-03-15
2008-03-25
Advanced Research And Technology Institute
Oral tolerance induction by collagen to prevent allograft rejection

CA2402489C
(en)

2000-03-15
2011-11-01
Advanced Research And Technology Institute
Oral tolerance induction by collagen to prevent allograft rejection

AU6481301A
(en)

2000-05-24
2001-12-03
Us Health
Methods for preventing strokes by inducing tolerance to e-selectin

PL215187B1
(en)

2000-08-21
2013-11-29
Apitope Technology Bristol Ltd
Tolerogenic peptide, pharmaceutical composition comprising this peptide, peptide or pharmaceutical composition for administration and application of the tolerogenic peptide

US7628988B2
(en)

2002-06-27
2009-12-08
The General Hospital Corporation
Methods and compositions for treating type 1 diabetes

US7582313B2
(en)

2002-06-27
2009-09-01
The General Hospital Corporation
Methods of organ regeneration using Hox 11-expressing pluripotent cells

AU2003290948A1
(en)

2002-11-15
2004-06-15
The General Hospital Corporation
Screening methods to identify treatments for autoimmune disease

US20080102054A1
(en)

2005-01-18
2008-05-01
Faustman Denise L
Compositions Containing Agm Cells And Methods Of Use Thereof

GB0710529D0
(en)

2007-06-01
2007-07-11
Circassia Ltd
Vaccine

EP2083856B1
(en)

2007-08-15
2010-09-29
Circassia Limited
Peptides for desensibilization against allergens

PL2953634T3
(en)

2013-02-07
2021-11-22
The General Hospital Corporation
Methods for expansion or depletion of t-regulatory cells

US10137181B2
(en)

2014-04-01
2018-11-27
INSERM (Institut National de la Santé et de la Recherche Médicale)
Isolated donor MHC-derived peptide and uses thereof

EP3294773A1
(en)

2015-05-15
2018-03-21
The General Hospital Corporation
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies

WO2017059132A1
(en)

2015-09-29
2017-04-06
The General Hospital Corporation
Methods of treating and diagnosing disease using biomarkers for bcg therapy

Citations (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU7653991A
(en)

1990-03-21
1991-10-21

Board Of Trustees Of The Leland Stanford Junior University

Improved major histocompatibility complex (mhc) molecules

1993

1993-03-05
US
US08/027,127
patent/US5593698A/en
not_active
Expired – Fee Related

1993-04-20
CA
CA002118502A
patent/CA2118502A1/en
not_active
Abandoned

1993-04-20
AU
AU41083/93A
patent/AU686101B2/en
not_active
Ceased

1993-04-20
HU
HU9403006A
patent/HUT71310A/en
unknown

1993-04-20
JP
JP5518673A
patent/JPH07505892A/en
not_active
Ceased

1993-04-20
KR
KR1019940703715A
patent/KR100275656B1/en
not_active
IP Right Cessation

1993-04-20
EP
EP93910671A
patent/EP0637249B1/en
not_active
Expired – Lifetime

1993-04-20
BR
BR9306345A
patent/BR9306345A/en
not_active
Application Discontinuation

1993-04-20
AT
AT93910671T
patent/ATE205400T1/en
not_active
IP Right Cessation

1993-04-20
IL
IL10547293A
patent/IL105472A/en
not_active
IP Right Cessation

1993-04-20
WO
PCT/US1993/003708
patent/WO1993020842A1/en
active
IP Right Grant

1993-04-20
DE
DE69330752T
patent/DE69330752D1/en
not_active
Expired – Lifetime

1994

1994-10-19
NO
NO943967A
patent/NO943967L/en
not_active
Application Discontinuation

Patent Citations (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU7653991A
(en)

1990-03-21
1991-10-21
Board Of Trustees Of The Leland Stanford Junior University
Improved major histocompatibility complex (mhc) molecules

Also Published As

Publication number
Publication date

KR100275656B1
(en)

2000-12-15

CA2118502A1
(en)

1993-10-28

EP0637249A4
(en)

1997-01-08

WO1993020842A1
(en)

1993-10-28

DE69330752D1
(en)

2001-10-18

AU4108393A
(en)

1993-11-18

KR950701228A
(en)

1995-03-23

IL105472A0
(en)

1993-08-18

HU9403006D0
(en)

1994-12-28

HUT71310A
(en)

1995-11-28

EP0637249B1
(en)

2001-09-12

NO943967D0
(en)

1994-10-19

IL105472A
(en)

1999-06-20

BR9306345A
(en)

1998-06-30

ATE205400T1
(en)

2001-09-15

US5593698A
(en)

1997-01-14

EP0637249A1
(en)

1995-02-08

NO943967L
(en)

1994-10-19

JPH07505892A
(en)

1995-06-29

Información de contacto